Retrospective Study of Optimized Sequential Antibody-Drug Conjugate Treatments for HER2-Low Breast Cancer

What this Trial Is About

Researchers are analyzing clinical data from patients with HER2-low breast cancer, a subtype defined by specific low levels of HER2 expression. This retrospective study focuses on patients treated with sequential antibody-drug conjugates ADCs, aiming to evaluate the effectiveness of different treatment sequences. It also explores resistance mechanisms and prognostic biomarkers by integrating genomic data such as HER2 expression changes and TROP2 levels, to better understand treatment responses and improve personalized care. The study examines various ADC regimens including trastuzumab deruxtecan, sacituzumab govitecan, RC48, SKB264, trastuzumab emtansine, and TQB2102 given in different sequences. Patients have received two or more ADCs sequentially. The analysis compares outcomes from different treatment strategies to identify optimal sequencing approaches and assess safety profiles. This is a non-intervention observational research study using existing clinical data. Participants involvement includes providing access to complete records of demographic information, tumor characteristics, laboratory and imaging tests, treatments, and follow-up data. Researchers will measure progression-free survival up to 12 months and overall survival up to 24 months from diagnosis. The study integrates genomic profiling with clinical data to identify biomarkers and resistance pathways, aiming to guide future personalized treatment strategies for HER2-low breast cancer patients.

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer